Diagnosis and treatment of bronchioloalveolar carcinoma

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 4, 2007, Pages 290-296

  Raz, Dan J ^a   Kim, Jae Y ^a   Jablons, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bronchioloalveolar carcinoma; Diagnosis; Epidermal growth factor receptor; Surgery; Therapy

Indexed keywords

BORTEZOMIB; CG 8123; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TRANSPLANTATION; NONHUMAN; REVIEW; THORAX RADIOGRAPHY; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; NEOPLASM STAGING; PNEUMONECTOMY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34249807906     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32816ebc62     Document Type: Review

References (65)

1. Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer 2006; 7:313-322. This is a comprehensive review of histopathology, radiographic findings, and treatment of BAC.
2. Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137-142.
3. Raz DJ, Glidden DV, Odisho AY, Jablons DM. Clinical characteristics and survival of patients with surgically resected incidentally detected lung cancer. J Thorac Oncol 2007; 2:125-130. An observational study on the characteristics of incidentally detected lung cancers. The relevance of BAC histology, which was found more commonly among incidentally detected cancers, is discussed.
4. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006; 30:606-613. A pathologic review of lung cancers detected in the Early Lung Cancer Action Program lung-cancer screening trial. Most resected tumors had BAC histology.
5. Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ 1992; 304:541-543.
6. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997; 89:1580-1586.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-532.
8. Beckmann MW, Niederacher D, Schnurch HG, et al. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997; 75:429-439.
9. Raz DJ, He B, Rosell R, Jablons DM. Current concepts in bronchioloalveolar carcinoma biology. Clin Cancer Res 2006; 12:3698-3704. A review of the uniqe tumor biology in BAC with an emphasis on the BAC-adenocarcinoma spectrum of disease.
10. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121:823-835.
11. Furak J, Trojan I, Szoke T, et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg 2003; 23:818-823.
12. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75:2844-2852.
13. Higashiyama M, Kodama K, Yokouchi H, et al. Prognostic value of bronchioloalveolar carcinoma component of small lung adenocarcinoma. Ann Thorac Surg 1999; 68:2069-2073.
14. Koga T, Hashimoto S, Sugio K, et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol 2002; 117:464-470.
15. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003; 27:937-951.
16. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004; 78:1728-1733.
17. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74:1640-1646.
18. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005; 23:3279-3287.
19. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005; 23:8396-8405.
20. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10:4227s-4232s.
21. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitorsensitive and -resistant EGFR mutants. PLoS Med 2005; 2:e313.
22. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9:485-495. The first description of a mouse model of BAC and adenocarcinoma based on an EGFR tyrosine kinase mutation.
23. Politi K, Zakowski MF, Fan PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20:1496-1510.
24. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118:257-262.
25. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
26. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
27. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in nonsmall-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-8092.
28. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with nonsmall cell lung cancer. Clin Cancer Res 2005; 11:3750-3757.
29. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-2501.
30. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23:857-865.
31. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
32. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93:355-363.
33. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in nonsmall cell lung cancer. Chest 2005; 128:317-321.
34. Haneda H, Sasaki H, Shimizu S, et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer 2006; 52:47-52. This study analyzes EGFR mutational status among patients with adenocarcinoma, mixed-BAC, and pure BAC.
35. Blons H, Cote JF, Le Corre D, et al. Epidermal growth factor receptor mutations in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol 2006; 30:1309-1315. This study of EGFR mutations reports a high proportion of BAC tumors with EGFR mutations in a European cohort, similar to numbers reported by Asian studies.
36. Gandara DR, Aberle D, Lau D, et al. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol 2006; 1:S20-S26. This is an excellent review of radiographic imaging of BAC.
37. Carretta A, Canneto B, Calori G, et al. Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchoalveolar carcinoma. Eur J Cardiothorac Surg 2001; 20:367-371.
38. Atkins KA. The diagnosis of bronchioloalveolar carcinoma by cytologic means. Am J Clin Pathol 2004; 122:14-16.
39. Raz DJ, Zell JA, Karnezis AN, et al. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thorac Oncol 2006; 1:943-948. This study reports the sensitivity and specificity of fine-needle-aspiration cytology in the diagnosis of both pure and mixed BAC. Most patients with BAC histology are misclassified as adenocarcinoma or unclassified NSCLC.
40. Okada M, Nishio W, Sakamoto T, et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004; 127:857-861.
41. Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of groundglass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer 2001; 33:17-25.
42. Jung JI, Kim H, Park SH, et al. CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia. Br J Radiol 2001; 74:490-494.
43. Takashima S, Li F, Maruyama Y, et al. Discrimination of subtypes of small adenocarcinoma in the lung with thin-section CT. Lung Cancer 2002; 36:175-182.
44. Yap CS, Schiepers C, Fishbein MC, et al. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002; 29:1166-1173.
45. Raz DJ, Odisho AY, Franc BL, Jablons DM. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 2006; 132:1189-1195. This study of the prognostic value of tumor SUV in patients with BAC histology found that tumors with SUV <2.5 were associated with a 95% 5-year survival, which was independent of tumor size.
46. Watanabe S, Watanabe T, Arai K, et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002; 73:1071-1075.
47. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001; 71:971-974.
48. Rusch VW, Tsuchiya R, Tsuboi M, et al. Surgery for bronchioloalveolar carcinoma and 'very early' adenocarcinoma: an evolving standard of care? J Thorac Oncol 2006; 1:S27-S31. This is an excellent review of surgical treatment of small BAC.
49. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol 2006; 17:1255-1262. This is a population-based study of patients with multifocal BAC, showing improved survival for patients with BAC histology compared with other lungcancer histologies.
50. Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal nonsmall cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg 2003; 126:1597-1602.
51. de Perrot M, Chernenko S, Waddell TK, et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004; 22:4351-4356.
52. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005; 23:3288-3293.
53. West HL, Crowley JJ, Vance RB, et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-h infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 2005; 16:1076-1080.
54. Scagliotti GV, Smit E, Bosquee L, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 2005; 50:91-96.
55. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353:123-132.
56. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol 2004; 22:1103-1109.
57. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97:339-346.
58. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in nonsmall-cell lung cancer. Br J Cancer 2004; 91:208-212.
59. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst 2005; 97:643-655.
60. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol 2006; 24:5034-5042. This was an analysis of EGFR expression by immunohistochemistry, copy number by FISH, and mutational analysis in a clinical trial of gefitinib for advanced-stage lung cancer.
61. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol 2005; 23:6838-6845.
62. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909.
63. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-3346. This study presents early results of a study of gefitinib for patients with lung cancer with EGFR mutations on biopsy.
64. Paz-Ares L, Sanchez JM, Garcia-Velasco BM. A prospective phase II trial of erlotinib in advanced nonsmall cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) [abstract]. J Clin Oncol 2006; 24 (18s):7020.
65. Han SW, Kim TY, Lee KH, et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated nonsmall-cell lung cancer patients. Lung Cancer 2006; 54:201-207.